Patents by Inventor Peter J. Olandt
Peter J. Olandt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110182879Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 46743, 27417, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 46743, 27417, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 46743, 27417, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: July 1, 2010Publication date: July 28, 2011Applicant: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Mark Williamson, Kevin R. Leiby, Rosana Kapeller-Libermann, Peter J. Olandt, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai, John J. Hunter
-
Publication number: 20100150901Abstract: The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies.Type: ApplicationFiled: October 22, 2008Publication date: June 17, 2010Applicant: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Kyle J. MacBeth, Rory A.J. Curtis, Laura A. Rudolph-Owen, Nadine S. Weich, Peter J. Olandt, Fong-Ying Tsai, Rosana Kapeller-Libermann, Joseph M. Carroll
-
Patent number: 7696316Abstract: The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted.Type: GrantFiled: October 19, 2006Date of Patent: April 13, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rosana Kapeller-Libermann, John Joseph Hunter, Rachel E. Meyers, Laura A. Rudolph-Owen, Rory A. J. Curtis, Peter J. Olandt, Fong-Ying Tsai, Katherine M. Galvin, Miyoung Chun, Mark J. Williamson, Inmaculada Silos-Santiago, Rajasekhar Bandaru
-
Publication number: 20090324608Abstract: The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.Type: ApplicationFiled: September 5, 2007Publication date: December 31, 2009Inventors: Rachel E. Meyers, Peter J. Olandt, Rosana Kapeller-Libermann, Rory A. J. Curtis, Mark Williamson, Nadine Weich
-
Patent number: 7485308Abstract: The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies.Type: GrantFiled: July 26, 2006Date of Patent: February 3, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Kyle J. MacBeth, Rory A. J. Curtis, Laura A. Rudolph-Owen, Nadine S. Weich, Peter J. Olandt, Fong-Ying Tsai, Rosana Kapeller-Libermann, Joseph M. Carroll
-
Patent number: 7301016Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted.Type: GrantFiled: June 27, 2002Date of Patent: November 27, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Mark Williamson, Kevin R. Leiby, Rosana Kapeller-Libermann, Peter J. Olandt, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai, John J. Hunter
-
Patent number: 7282360Abstract: The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.Type: GrantFiled: December 11, 2006Date of Patent: October 16, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Peter J. Olandt, Rosana Kapeller-Libermann, Rory A. J. Curtis, Mark Williamson, Nadine Weich
-
Patent number: 7070947Abstract: The invention provides isolated nucleic acids molecules, designated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, hexokinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.Type: GrantFiled: June 13, 2002Date of Patent: July 4, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Peter J. Olandt, Rosana Kapeller-Libermann, Rory A. J. Curtis, Mark Williamson, Nadine Weich
-
Patent number: 6939698Abstract: The invention provides isolated nucleic acids molecules, designated 33945 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33945 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33945 gene has been introduced or disrupted. The invention still further provides isolated 33945 proteins, fusion proteins, antigenic peptides and anti-33945 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: February 12, 2002Date of Patent: September 6, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventors: Peter J. Olandt, Rachel E. Meyers, Katherine M. Galvin
-
Publication number: 20040058355Abstract: The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted.Type: ApplicationFiled: April 25, 2003Publication date: March 25, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Rosana Kapeller-Libermann, John Joseph Hunter, Rachel E. Meyers, Laura A. Rudolph-Owen, Rory A. J. Curtis, Peter J. Olandt, Fong-Ying Tsai, Katherine M. Galvin, Miyoung Chun, Mark J. Williamson, Inmaculada Silos-Santiago, Rajasekhar Bandaru
-
Publication number: 20040005664Abstract: The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies.Type: ApplicationFiled: April 10, 2003Publication date: January 8, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Rachel E. Meyers, Kyle J. MacBeth, Rory A. J. Curtis, Laura A. Rudolph-Owen, Nadine S. Weich, Peter J. Olandt, Fong-Ying Tsai, Rosana Kapeller-Libermann, Joseph M. Carroll
-
Publication number: 20040005685Abstract: The invention provides isolated nucleic acids molecules, designated 97316 nucleic acid molecules, which encode novel amine oxidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 97316 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 97316 gene has been introduced or disrupted. The invention still further provides isolated 97316 proteins, fusion proteins, antigenic peptides and anti-97316 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 3, 2003Publication date: January 8, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Peter J. Olandt, Mark J. Williamson
-
Publication number: 20030224376Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted.Type: ApplicationFiled: June 27, 2002Publication date: December 4, 2003Inventors: Rachel E. Meyers, Mark Williamson, Kevin R. Leiby, Rosana Kapeller-Libermann, Peter J. Olandt, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai, John J. Hunter
-
Publication number: 20030180930Abstract: The invention provides isolated nucleic acids molecules, designated 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, hexokinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2504, 15977, 14760, 53070, 15985, 50365, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.Type: ApplicationFiled: June 13, 2002Publication date: September 25, 2003Inventors: Rachel E. Meyers, Peter J. Olandt, Rosana Kapeller-Libermann, Rory A. J. Curtis, Mark Williamson, Nadine Weich
-
Publication number: 20030087250Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.Type: ApplicationFiled: March 14, 2002Publication date: May 8, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: John E. Monahan, Manjula Gannavarapu, Sebastian Hoersch, Shubhangi Kamatkar, Steven G. Kovats, Rachel E. Meyers, Michael P. Morrisey, Peter J. Olandt, Ami Sen, Petter Ole Veiby, Gordon B. Mills, Robert C. Bast, Karen Lu, Rosemarie E. Schmandt, Xumei Zhao, Karen Glatt
-
Publication number: 20020142426Abstract: The invention provides isolated nucleic acids molecules, designated 33945 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33945 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33945 gene has been introduced or disrupted. The invention still further provides isolated 33945 proteins, fusion proteins, antigenic peptides and anti-33945 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: February 12, 2002Publication date: October 3, 2002Inventors: Peter J. Olandt, Rachel E. Meyers, Katherine M. Galvin
-
Publication number: 20020115630Abstract: The invention provides isolated nucleic acids molecules, designated 33449 nucleic acid molecules, which encode novel protease or S26 signal peptidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33449 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33449 gene has been introduced or disrupted. The invention still further provides isolated 33449 proteins, fusion proteins, antigenic peptides and anti-33449 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: January 14, 2002Publication date: August 22, 2002Inventors: Rachel E. Meyers, Peter J. Olandt